Intuitive Surgical, Inc. (ISRG) Stock Analysis

Intuitive Surgical’s primary competitive advantage is its entrenched leadership in robotic-assisted surgery, anchored by the da Vinci platform. With over 11,000 systems installed globally and more than 17 million procedures performed, ISRG enjoys a network effect that new entrants struggle to replicate. Its installed base is several times larger than that of any competitor, such as Medtronic or Johnson & Johnson, both of whom remain in early commercialization phases with limited FDA approvals and narrower clinical indications.

ISRG’s “razor-and-blades” model—selling high-margin instruments and accessories for each procedure—yields recurring revenue, which comprised 86% of total revenue in Q1 2026. This model supports robust gross margins (66% in 2025) and funds industry-leading R&D, with $1.3 billion invested in 2025 alone. The company’s intellectual property portfolio, with over 5,600 active patents, creates significant barriers to entry.

Customer loyalty is reinforced by high switching costs: hospitals invest heavily in training, workflow integration, and multi-year service contracts. Surgeon familiarity and preference further entrench ISRG’s position, as evidenced by rising utilization rates per system.

While rivals are increasing investment, ISRG’s scale, regulatory experience, and data-driven digital ecosystem (including AI-enabled analytics and training) provide a durable moat. Risks include pricing pressure in China, emerging competition, and potential disruption from alternative therapies, but ISRG’s breadth, brand, and execution remain unmatched in the sector.